Stock News

Mpm Asset Management Maintains Stake in Conatus Pharmaceuticals (CNAT); Viacom New (VIAB) Share Price Declined While Rmb Capital Management Has Cut Its Position

Viacom, Inc. (NASDAQ:VIAB) Logo

Rmb Capital Management Llc decreased its stake in Viacom Inc New (VIAB) by 8.18% based on its latest 2017Q4 regulatory filing with the SEC. Rmb Capital Management Llc sold 26,944 shares as the company’s stock declined 4.65% with the market. The hedge fund held 302,504 shares of the television services company at the end of 2017Q4, valued at $9.32M, down from 329,448 at the end of the previous reported quarter. Rmb Capital Management Llc who had been investing in Viacom Inc New for a number of months, seems to be less bullish one the $12.56B market cap company. The stock decreased 0.07% or $0.02 during the last trading session, reaching $30.64. About 243,634 shares traded. Viacom, Inc. (NASDAQ:VIAB) has declined 30.65% since April 23, 2017 and is downtrending. It has underperformed by 42.20% the S&P500.

Mpm Asset Management Llc increased its stake in Conatus Pharmaceuticals Inc. (CNAT) by 76.26% based on its latest 2017Q4 regulatory filing with the SEC. Mpm Asset Management Llc bought 909,091 shares as the company’s stock rose 13.83% while stock markets declined. The institutional investor held 2.10M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $9.71M, up from 1.19M at the end of the previous reported quarter. Mpm Asset Management Llc who had been investing in Conatus Pharmaceuticals Inc. for a number of months, seems to be bullish on the $104.31 million market cap company. The stock decreased 2.80% or $0.1 during the last trading session, reaching $3.47. About 77,538 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 12.92% since April 23, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Investors sentiment decreased to 1.1 in 2017 Q4. Its down 0.73, from 1.83 in 2017Q3. It dived, as 14 investors sold CNAT shares while 17 reduced holdings. 11 funds opened positions while 23 raised stakes. 11.71 million shares or 7.58% more from 10.89 million shares in 2017Q3 were reported. 22,011 were reported by Reilly Limited. Barclays Plc reported 4,170 shares or 0% of all its holdings. Schwab Charles Investment Management holds 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) or 180,556 shares. Meeder Asset Management holds 0% or 2,376 shares in its portfolio. Macquarie Grp Limited reported 130,300 shares. Tower Capital Limited Liability Co (Trc) has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Geode Capital Limited Liability, a Massachusetts-based fund reported 429,556 shares. Financial Architects has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Comml Bank Of New York Mellon has invested 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 16,800 shares in its portfolio. State Street holds 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) or 402,414 shares. 141,700 were reported by Arrowstreet Cap Lp. Ameritas Invest Partners holds 0% or 2,246 shares in its portfolio. 21,804 are owned by One Trading Ltd Partnership. Renaissance Techs Limited Co, a New York-based fund reported 28,757 shares.

Among 7 analysts covering Conatus Pharma (NASDAQ:CNAT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 16 analyst reports since September 22, 2015 according to SRatingsIntel. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has “Buy” rating given on Thursday, March 1 by Oppenheimer. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, November 5. As per Thursday, August 3, the company rating was maintained by Stifel Nicolaus. As per Tuesday, December 20, the company rating was maintained by Stifel Nicolaus. H.C. Wainwright maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) rating on Thursday, April 5. H.C. Wainwright has “Buy” rating and $15 target. The firm has “Buy” rating given on Wednesday, November 9 by Stifel Nicolaus. The stock has “Buy” rating by Oppenheimer on Thursday, March 22. The stock has “Buy” rating by Roth Capital on Friday, July 1. H.C. Wainwright initiated the stock with “Buy” rating in Tuesday, September 22 report. The firm has “Buy” rating given on Thursday, June 29 by H.C. Wainwright.

Among 39 analysts covering Viacom Inc. (NASDAQ:VIAB), 13 have Buy rating, 0 Sell and 26 Hold. Therefore 33% are positive. Viacom Inc. had 135 analyst reports since August 7, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Viacom, Inc. (NASDAQ:VIAB) rating on Friday, August 7. Stifel Nicolaus has “Buy” rating and $70 target. The stock has “Buy” rating by Deutsche Bank on Sunday, August 23. Wunderlich maintained the shares of VIAB in report on Friday, August 7 with “Buy” rating. The rating was maintained by Topeka Capital Markets with “Hold” on Wednesday, December 23. Barclays Capital maintained Viacom, Inc. (NASDAQ:VIAB) rating on Friday, October 20. Barclays Capital has “Equal-Weight” rating and $32 target. UBS maintained the shares of VIAB in report on Thursday, September 22 with “Buy” rating. The stock has “Buy” rating by UBS on Monday, June 20. On Friday, August 26 the stock rating was maintained by Telsey Advisory Group with “Market Perform”. The firm earned “Market Perform” rating on Tuesday, September 5 by Wells Fargo. The firm has “Mkt Perform” rating by FBR Capital given on Monday, April 10.

Rmb Capital Management Llc, which manages about $3.98B and $3.85 billion US Long portfolio, upped its stake in Alliancebernstein Natl Muni (AFB) by 57,560 shares to 78,553 shares, valued at $1.05M in 2017Q4, according to the filing. It also increased its holding in Ishares Tr (PFF) by 74,099 shares in the quarter, for a total of 204,838 shares, and has risen its stake in Northern Tr Corp (NASDAQ:NTRS).

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *